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Abstract The phosphatidylinositol 3-kinase (PI3K) path-
way is a critical signal transduction pathway that regulates
multiple cellular functions. Aberrant activation of this
pathway has been identified in a wide range of cancers.
Several pathway components including AKT, PI3K and
mTOR represent potential therapeutic targets and many
small molecule inhibitors are in development or early
clinical trials. The complex regulation of the pathway,
together with the multiple mechanisms by which it can be
activated, make this a highly challenging pathway to
target. For successful inhibition, detailed molecular
information on individual tumours will be required and
it is already clear that different tumour types show
distinct combinations of alterations. Recent results have
identified alterations in pathway components PIK3CA,
PTEN, AKT1 and TSC1 in bladder cancer, some of which
are significantly related to tumour phenotype and clinical
behaviour. Co-existence of alterations to several PI3K
pathway genes in some bladder tumours indicates that
these proteins may have functions that are not related
solely to the known canonical pathway.
Keywords Bladder cancer.PI3Kpathway.PTEN.
PIK3CA.AKT1.TSC1
1 Introduction
The phosphatidylinositol 3-kinase (PI3K) pathway (Fig. 1)
plays a pivotal role in cell growth, proliferation and
survival [1] and signalling via this pathway is upregulated
in many types of cancer [2, 3]. Genomic alterations have
been detected in multiple genes in the pathway. These
include the tumour suppressor genes PTEN and LKB1,
which are inactivated by mutation and/or deletion in many
sporadic cancers [4, 5] and the protooncogenes AKT1,
AKT2, PDK1 and PIK3CA that are activated by mutation or
amplification [6–9]. Other mutations and alterations in gene
expression in cancer also contribute to aberrant activation
of the pathway. For example, oncogenic activation of the
RAS genes by point mutation activates the pathway via the
interaction of RAS with p110α, the catalytic subunit of PI3
kinase [10]. Increased signalling via the epidermal growth
factor family (ERBB) receptors also activates the pathway.
The mTOR pathway can also be activated downstream of
RAS via ERK-mediated negative regulation of the TSC1/
TSC2 complex [11]. Several of the activated protoonco-
genes represent potential targets for therapy and there is
currently much interest in developing agents to target these
proteins.
The mechanisms by which the pathway is activated are
somewhat tissue specific. For example, PTEN is inactivated
predominantly by mutation in certain cancer types but in
others the major mechanism of inactivation is genomic
homozygous deletion (HD) [4]. Some tumour types show
mutual exclusivity of different events in the pathway and
others do not [12]. Thus, for rational application of PI3K
pathway-targeted agents, comprehensive information on
pathway activation status and mechanisms of activation is
needed for specific tumour types. Several mechanisms have
been identified by which the PI3K pathway is activated in
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recent findings and relate these to the major UC subtypes
and potential therapeutic approaches.
2 Bladder cancer subtypes
Bladder cancers fall into two major groups with distinct
pathology and clinical behaviour and different molecular
profiles [13–15]. Non-invasive papillary tumours and
muscle-invasive tumours represent distinct groups that at
least in the majority of cases, do not represent a
developmental continuum [13, 15]. Muscle-invasive blad-
der cancer (T2-T4) is thought to develop via flat dysplasia
and carcinoma in situ (CIS) and these tumours are usually
of non-papillary architecture. Non-invasive (Ta) tumours
are believed to arise via flat urothelial hyperplasia followed
by development of an exophytic papillary architecture.
These represent the two ends of a spectrum within which lie
the group of T1 papillary tumours that invade the
submucosa but not muscle. For T1 tumours, diagnosis and
prediction of clinical course are difficult and it is not clear
how the pathogenesis of this group relates to that of the Ta
and muscle invasive tumours (T2-4). Figure 2 shows the
proposed pathogenesis of the two major groups of bladder
tumours and possible relationships to T1 disease. A
hypothetical third pathogenesis pathway involving initial
flat dysplasia leading to the development of high-grade
papillary tumours is included though evidence for this is
currently lacking. Papillary T1 tumours could develop via
this route.
Recent molecular studies have implicated PI3K pathway
alterations in UC of all grades and stages. However, some
associations with particular groups have been identified and
will be discussed below. It is clear that for full biological
understanding and rational application of therapeutic
agents, precise information on the timing and pathological
associations of these molecular alterations and their
interactions and/or co-operation with other events will be
required.
3 PI3K pathway
PI3 kinases are heterodimers comprised of a regulatory
subunit (p85) and a catalytic subunit (p110). Activated
receptor tyrosine kinases recruit the PI3 kinase complex to
the membrane via the p85 regulatory subunit either
directly or via insulin receptor substrate adapter proteins,
activating the catalytic subunit p110, which then phos-
phorylates phosphatidylinositol-4,5-bisphosphate (PIP2) to
phosphatidylinositol-3,4,5-trisphosphate (PIP3). Phospha-
tase and tensin homologue deleted on chromosome 10
(PTEN) catalyses the reverse reaction. PIP3 recruits
protein dependent kinase 1 (PDK1) and AKT, also known
as protein kinase B (PKB), to the plasma membrane
where AKT is phosphorylated at Thr308 by PDK1 and at
Ser473 by mTOR complex 2 (TORC2) [16]. AKT1 can
also be phosphorylated at Ser473 by DNA-PK in the
nucleus [17]. AKT occupies a key regulatory node in the
PI3K pathway, below which the pathway branches signif-
icantly to influence a wide range of cellular processes that
promote cell cycle progression, cell growth, energy metab-
olism and resistance to apoptosis. One of the major
effectors downstream of AKT is mTOR complex 1
(TORC1), which integrates inputs related to growth-factor
signalling and nutrient and oxygen availability to regulate
protein synthesis (Fig. 1).
In bladder cancer, mutations have been identified in
p110α (PIK3CA), AKT1, TSC1 and loss of heterozygosity
(LOH), homozygous deletion and inactivating mutations of
PTEN have been found [18–21].
3.1 PIK3CA
There are three isoforms of class IA p110 (p110α,p 1 1 0 β
and p110δ). All have similar structure with domains for
binding to the adaptor protein PIK3R1 (p85) and to RAS
(Fig. 3a). To date, most evidence from human cancers
implicates p110α (PIK3CA) with activating mutations and/
or amplification identified in a wide range of tumour types
[22].
Fig. 1 The class IA PI3K signalling pathway
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significant proportion of tumours, including many Ta
tumours. The overall frequency in a series of tumours
comprising 35.4% Ta, 39.2% T1 and 25.4% T2 tumours
was 27% [23]. In a study that examined a larger proportion
of Ta tumours (65.5% Ta, 11.5% Ta, 23% T2), a significant
association of mutation with low grade and stage was found
[24], though overall frequency was lower (13%). The
difference in frequency in these studies may reflect the
screening of only hotspot exons in the study of Lopez-
Knowles et al., although this is unlikely as only two
mutations outside these hotspot regions were identified in
the first study. Possibly, the difference may be attributed to
differences in sensitivity of the mutation-screening
approaches used (direct sequencing vs. scanning by high-
resolution melting followed by sequencing). Further studies
are needed to clarify the exact frequency and distribution of
these mutations according to tumour grade and stage. The
recent development of a low-cost, high throughput assay to
detect the common variants should facilitate this [25].
Interestingly, the PIK3CA mutation spectrum in UC
differs significantly from that in other cancers. Figure 3b
shows the spectrum of mutations in UC [23] and that
reported in COSMIC (www.sanger.ac.uk/genetics/CGP/
cosmic/). Mutations E542K and E545K in the helical
domain are most common and the kinase domain mutation
H1047R which is the most common mutation in other
cancers is less common in UC. In total, 9 different
mutations have been found to date [23] (Fig. 3a). Mutations
resulting in amino acid changes P124L, Q643R, D1017H
and M1043I were confirmed as somatic by comparison
with matched normal DNA. The mutation A1066V found
in the cell line 639V could not be confirmed as somatic as
paired normal DNA is not available for this cell line. Apart
Fig. 3 Mutations of PIK3CA
identified in bladder cancer. a
Schematic representation of the
protein showing functional
domains and the position of
mutations identified to date.
Both the adapter-binding and C2
domains interact with p85. b
Comparison of PIK3CA muta-
tions in bladder cancer and those
listed in COSMIC for positions
M1043, H1047, E542 and E545
excluding bladder tumour muta-
tions modified from [23]
Fig. 2 Potential pathways of
urothelial tumorigenesis. Solid
arrows indicate likely pathways
and broken arrows indicate un-
certain relationships. Low-grade
papillary tumours (left) may
arise via simple hyperplasia and
minimal dysplasia. Invasive
carcinoma (right) is believed to
arise via the flat high-grade
lesion CIS. A third hypothetical
pathway to development of high
grade papillary tumours is
shown (middle). The pathway to
development of T1 tumours is
uncertain
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hotspot mutations and therefore predicted to affect protein
function in similar ways. P124L lies in a region of four
helices in the protein between the adapter-binding and
RAS-binding domains, the function of which is not known.
However, a missense mutation in codon 124 (P124T) has
been reported in a colorectal cancer [26] suggesting that
this may be an activating mutation. Functional studies are
now required to confirm this.
The selective pressure for helical domain mutation in UC
is not yet understood. Recent studies of the structure of
p110α and the effect of the common activating mutations
have revealed different mechanisms of activation by helical
domain and kinase domain mutations [22]. In functional
assays, H1047R was shown to be dependent on p85
binding but not on RAS binding and, conversely, the
helical domain mutations E542K and E545K were shown
to require RAS binding but not p85 binding. This raises the
possibility that there may be co-operation between these
helical domain PIK3CA mutant proteins and other events in
UC that are known to activate RAS including mutations of
the RAS genes themselves [27], epidermal growth factor
receptor (EGFR) overexpression and FGFR3 mutation [28].
It is interesting that mutations in FGFR3 and PIK3CA are
also found commonly in the benign skin lesions seborrheic
keratosis and epidermal nevi [29]. As many Ta papillary
bladder tumours can be considered benign, these molecular
alterations may be hallmarks of benign epithelial over-
growth conditions.
3.2 PTEN
PTEN is a multifunctional phosphatase whose major lipid
substrate is PIP3 generated at the cell membrane by PI3K.
PTEN can also dephosphorylate a range of protein targets
including Shc and FAK [30]. PTEN is found not only at the
cell membrane and in the cytoplasm but also in the nucleus
where it is believed to exert additional tumour-suppressive
functions (reviewed in [31]). Deletions of 10q including the
PTEN region are found in 24-58% of invasive UC [18, 20,
32] and only infrequently in low-grade papillary non-
invasive UC. In contrast to some other tumour types,
mutations on the retained allele of PTEN are not detected
frequently in UC [19–21, 33], but HD has been identified in
a few cases.
Recent studies have shown that reduced PTEN protein
expression is common in UC [23, 34, 35]. PTEN is
haploinsufficient in mouse models [36] and findings in
UC to date are compatible with a phenotypic effect of
reduced expression in the urothelium. Downregulation of
PTEN expression is more frequent in invasive UC and is
commonly associated with p53 alteration. Thus, 41% of
tumours with altered p53 also showed downregulation of
PTEN and this combined alteration of p53 and PTEN was
associated with poor patient outcome [35]. To date, only a
single study has examined pathway activation status in UC.
Western blot analysis of levels of phosphorylated AKT
revealed that 55% had significantly higher levels than
normal controls. These included five of 11 superficial
tumours and six of 11 invasive tumours [37].
Based on the observation that PTEN functions in both
nucleus and cytoplasm, two studies have examined nuclear
and cytoplasmic PTEN expression separately [23, 34].
Results were concordant, each study showing that nuclear
staining was reduced more frequently than cytoplasmic
staining [23, 34]. Reduced PTEN expression was signifi-
cantly associated with tumour grade, stage or both. Figure 4
shows examples of PTEN protein expression patterns in UC
and Fig. 5 shows the distribution of nuclear and cytoplas-
mic expression according to grade and stage in our recent
study [23].
UC cell lines have also been assessed for allelic status of
PTEN, copy number reduction by array CGH and protein
expression. Several lines have homozygous deletion of
PTEN (J82, UM-UC3, DSH1) and two (T24 and 639 V) are
known to contain missense mutations. Overall, 46% of UC
lines examined recently had alterations that implicated
PTEN [23]. As all but one of these lines was derived from
invasive UC, these findings are compatible with what has
been observed in muscle invasive bladder tumour tissues.
The protein phosphatase activity of PTEN influences cell
motility via its action on proteins involved in cytoskeletal
re-modelling. In glioma, protein phosphorylation activity of
PTEN controls FYN kinase to regulate cell migration in a
PI3K pathway-independent manner [38]. It has been shown
previously that the germline mutation of PTEN, G129E,
which is found in Cowden syndrome, results in loss of the
lipid phosphatase activity of the protein but not its protein
phosphatase activity. This has led to a major focus on the
lipid phosphatase activity of PTEN and less focus on the
consequences of its activity as a protein phosphatase.
A critical role for activation of the PI3K pathway in UC
cell lines has been demonstrated by the finding that the
PI3K inhibitor LY294002, but not a MEK1/2, inhibitor
suppressed the invasive properties of T24, J82 and UM-
UC3 cell lines, all of which have PTEN defects [37]. Re-
expression of wild-type PTEN or expression of a dominant
negative AKT also suppressed invasion, confirming that
these cells are dependent on activation of the PI3K pathway
for their invasive phenotype. This effect of PTEN re-
expression in J82 was subsequently confirmed in an
independent study [39]. The G129E mutant form of PTEN
has been used to demonstrate that the invasive phenotype of
T24, which contains a mutation in PTEN, can be inhibited
by the protein phosphatase activity of PTEN alone [40].
This phenotype is likely to be of critical importance in the
308 Cancer Metastasis Rev (2009) 28:305–316invasive bladder tumours in which PTEN downregulation is
most commonly seen. The recent finding of frequent
mutation of PIK3CA in low grade and stage UC, which is
presumed to phenocopy the effects of loss of the lipid
phosphatase activity of PTEN, points to a role for non-
canonical activities of PTEN, possibly via its protein
phosphatase activity, in invasive UC. Further studies are
required to understand exactly how these two enzymatic
functions of PTEN play a role in the two major groups of
UC.
Fig. 5 Distribution of nuclear
and cytoplasmic staining inten-
sities for PTEN according to
bladder tumour grade and stage.
Reprinted from [23]
Fig. 4 Patterns of staining for PTEN protein in urothelial tumours.
Scores are nuclear followed by cytoplasmic intensity. Normal ureter is
shown as control. Staining in tumour samples was scored as 2 if it was
at least as strong as the staining in controls, 1 if detectable but reduced
and 0 if staining was absent. In tumour samples with scores of 1,2;
1,1; 0,1; 0,0 stromal cells with intense staining act as positive controls.
All images were captured at same magnification. Reprinted from [23]
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loss to bladder cancer development in mouse models [35].
Conditional deletion of Pten in the urothelium led to early
urothelial hyperplasia [34, 41]. Increased cell size was
observed, compatible with mTOR activation, and PI3K
pathway activation was confirmed by detection of phospho-
AKT [34]. UC developed late in these animals and was
typically pedicellate papillary transitional cell carcinoma,
resembling human papillary superficial tumours. Develop-
ment of these tumours could be precipitated by treatment
with the known bladder carcinogen butyl-N-(4-hydroxybu-
tyl)nitrosamine. A more recent study used adenovirus-
delivered Cre recombinase to induce stochastic deletion of
p53 and/or Pten in mice carrying floxed alleles [35].
Deletion of either gene alone did not lead to tumour
formation but dual deletion led to the early development of
aggressive tumours, which frequently metastasised, provid-
ing a model of aggressive human UC with inactivation of
both of these tumour suppressor genes.
3.3 AKT1
AKT1 is one of three family members of serine-threonine
kinases that are activated by phosphorylation of Thr308 by
PDK1 and Ser473 by TORC2 (Fig. 1). Recently, an
activating mutation in the pleckstrin homology domain of
AKT1 was identified in breast, colorectal and ovarian
cancers [9]. Glu 17 plays a pivotal role in activation of
AKT1 due to its location in the phosphoinositide-binding
pocket. The change to lysine introduces a positive change
that alters phosphoinositide affinity and the mutant protein
is aberrantly translocated to the membrane resulting in
constitutive downstream signalling.
The same mutation has been identified in other cancers
including bladder [42]. G49A (E17K) was found in two of
44 (4.8%) bladder cancer cell lines and five of 184 (2.7%)
UC tumour samples. In cell lines containing the mutation,
AKT1 activation was retained under conditions of growth
factor withdrawal. A novel mutation, G145A (E49K), was
also found in one cell line. This mutation also enhanced
AKT activation and was transforming in NIH3T3 cells.
Functional studies using retroviruses to deliver wild-type
AKT1 or the two mutants singly or in tandem, indicated
enhanced activation of AKT1 when E17K and E49K
mutations were in tandem suggesting that they can co-
operate. However, the E49K mutation was not found in a
series of 184 UC tumour samples indicating that it does not
contribute to the development of the majority of UC.
3.4 TSC1
TSC1 is one of two genes that when mutated in the
germline cause the syndrome tuberous sclerosis complex
(TSC), an autosomal dominant tumour-suppressor gene
syndrome characterised by the development of hamartomas
in the kidneys, heart, brain and skin [43]. TSC1 on
chromosome 9q34 encodes hamartin [44] and TSC2 on
chromosome 16p13.3 encodes tuberin [45]. Tumour devel-
opment in TSC patients is thought to occur as the result of a
somatic ‘second-hit’ in one of these genes.
Co-localisation and co-immunoprecipitation of TSC1
and TSC2 in mammalian cells [46, 47] and binding in
yeast two-hybrid assays, provides evidence for direct
interaction of the two proteins and a rationale for the
similar disease phenotype in patients with mutations in
either gene [44, 48]. Functionally, the TSC1/TSC2 complex
is positioned downstream of AKT where TSC2 is directly
phosphorylated and inactivated by AKT. Activation of the
complex in growth-limiting conditions attenuates signalling
through mTOR via specific GTPase activating protein
activity of TSC2 towards the small GTPase RHEB [49,
50]. Inactivation of the complex leads to enhanced
signalling via mTOR.
Although epithelial malignancy is not a common feature
of TSC, loss of function of TSC1 has been identified in UC
[23, 51, 52]. To date, no other human malignancies have
been shown to contain mutations in either of the TSC
genes. LOH for markers on chromosome nine is observed
in more than 50% of bladder tumours of all grades and
stages [53] and sub-chromosomal LOH analyses have
identified the TSC1 locus at 9q34 as a common critical
region of deletion between markers D9S149 and D9S66
[51, 54–56]. Studies to date indicate an overall TSC1
mutation frequency of 14.5% in UC. The mutation
spectrum comprises nonsense (35%), missense (26%),
frameshift (26%), in-frame deletions (3%) and splicing
(10%) mutations [23, 57] (Fig. 6). Missense mutations of
TSC1 found in UC were shown to cause loss of function
through aberrant splicing, protein instability or protein
mislocalisation [58]. More recently, it has become apparent
that such mechanisms of inactivation via missense mutation
are also found in TSC disease [59, 60].
It has been suggested that TSC1 is haploinsufficient in
some lesions in patients with germline mutation [61] and
we previously found apparent heterozygosity for mutations
in UC tumour samples [57]. Recently, we analysed a series
of tumours more carefully to assess possible haploinsuffi-
ciency and found only one case with mutation in which the
wild-type allele of TSC1 was retained. This tumour
contained the missense mutation F216A and continued to
express hamartin [23]. Previously, we have shown altered
localisation of this mutant protein when re-expressed in
TSC1-null urothelial cells and unlike other somatic mis-
sense mutants, there is no splicing defect or reduced protein
stability [58] pointing to altered function (possibly domi-
nant negative) rather than haploinsufficiency in this case.
310 Cancer Metastasis Rev (2009) 28:305–316Immunohistochemical analysis of hamartin expression in
UC tissues does, however, reveal a range of levels of
protein expression in tumours that do not carry a mutation
(Fig. 7) indicating that other mechanisms of regulation of
expression may play a role in reducing TSC1 function in
UC.
As tuberin represents the active partner in the TSC1/
TSC2 complex, somatic inactivation of TSC2 could have
more profound effects than inactivation of TSC1. Indeed,
germline TSC2 mutations cause a more severe phenotype
than TSC1 mutations [62]. TSC2 is a large gene and has not
been screened for mutation in UC. LOH analysis of the
TSC2 gene region has revealed only 15% LOH and array-
based CGH analysis has shown underrepresentation of the
TSC2 region in only 9.7% of cases indicating that biallelic
inactivation of TSC2 is unlikely to be common in UC [23].
3.5 Upstream activators of the PI3 kinase pathway
The pathway is activated by a range of receptor tyrosine
kinases. These include the ERBB family of receptors,
EGFR, ERBB2, ERBB3 and ERBB4. ERBB3 interacts
Fig. 6 TSC1 mutation spectrum in tuberous sclerosis complex and in bladder cancer. Amino acid positions of reported functional domains of
hamartin are shown
Fig. 7 Patterns of staining for the TSC1 protein product hamartin in
bladder tumours. a Normal ureter. b-j Bladder tumour tissues. b, c, d
and e illustrate the range of staining intensity in positive-staining
tumours. f-j show loss of hamartin expression. In i, the tumour shows
loss of expression and a region of normal urothelium is present at the
bottom of the image. Reprinted from [23]
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via RAS. Although there has been some conflicting
evidence, most studies of UC report over-expression of
EGFR, ERBB2 and/or ERBB3 in subsets of cases (e.g.,
[64–69]). High-level expression of EGFR is associated with
higher tumour grade and stage and with decreased
recurrence-free interval [70]. ERBB2 and ERBB3 expres-
sion is associated with high tumour grade and stage, though
it is not clear whether this provides predictive or prognostic
information [71, 72]. ERBB4 has been reported to show
reduced expression in tumours compared with normal
urothelium [70]. Further information is needed on the
expression of these receptors and their ligands in UC but it
is clear that activation of the PI3 kinase pathway in many
advanced cases of UC may be driven by one of more
members of this family.
Other receptor tyrosine kinases that are known to
activate the pathway include KIT, RON (MST1R),
P D G F R Aa n dM E T .T h e r ei sn oi n f o r m a t i o no nt h e
expression of KIT or PDGFRA in UC. However, MET
and RON expression is upregulated in aggressive UC [73–
75]. Expression status of these proteins has not yet been
examined in relation to PI3K pathway activation status.
N-cadherin is upregulated in UC, mainly in invasive
tumours [76], and it has been shown that ectopic expression
of this cadherin in UC cell lines induces cell invasion [77].
This was associated with activation of the PI3K pathway
and was inhibited by both PI3K and SRC inhibitors. The
exact mechanism by which N-cadherin activates the
pathway remains to be elucidated.
RAS proteins interact directly with p110α. Activating
mutations in one of the three RAS genes are found in 13%
of UC [27]. These are predominantly in HRAS and KRAS
([27]; Hurst et al., unpublished), but a few NRAS mutations
have also been identified. There appears to be no
association of mutation with clinico-pathological parame-
ters. It is predicted that the PI3K pathway is activated
directly by RAS in these tumours.
Finally, it is possible that activating mutation or over-
expression of FGFR3 can activate the pathway in UC. RAS
and FGFR3 mutations are mutually exclusive in these
tumours, suggesting that they may fulfil overlapping
functions [27]. Mutant FGFR3 has been confirmed to
activate the RAS-MAPK pathway in normal human
urothelial cells, though in this normal cell context,
activation of the PI3K pathway was not detected [78]. It
has been observed that although RAS and FGFR3 mutation
are mutually exclusive, the grade and stage distribution of
these events is different, FGFR3 mutations being most
common in low-grade Ta tumours and RAS mutations
being distributed evenly across tumours of all grades and
stages. This could indicate differences in downstream
effector mechanisms and PI3K pathway activation is a
candidate for such a difference. It will be important to
examine the effects of FGFR3 in the context of urothelial
tumour cells rather than normal cells and to explore the
pathway activation status and clinical outcome of UC with
RAS mutation in comparison with those of similar grade
and stage with FGFR3 mutation.
3.6 Other genes in the pathway
It is possible that other genes in the pathway are altered in
UC. To date, screening of only LKB1 and RHEB has been
reported [23]. No mutations were found in RHEB.
LKB1 is a serine threonine kinase that activates AMP-
activated protein kinase [79] and negatively regulates
mTOR signalling via TSC1/TSC2 [80]. Germline mutation
of LKB1 causes Peutz-Jegher’s syndrome, a multiple
hamartoma syndrome with a range of benign tumours
including a few in the ureter and bladder [81]. In UC, only
a single somatic mutation, a missense change (Q100E) was
found, indicating that LKB1 is not a critical mutation target
in UC unlike other sporadic cancers [82]. The functional
significance of this missense change is unknown. In other
tumour types, however, the majority of mutations reported
are protein-truncating (stop or frameshift).
Other candidate genes that merit examination are
PIK3R1 (p85), mutations of which have been reported at
low frequency in other epithelial cancers [6], AKT2, AKT3,
PDK1 and FLCN, which when mutated in the germline
causes Birt-Hogg-Dubé syndrome, characterised by benign
skin, kidney and lung lesions [83].
3.7 Relationship of pathway alterations
If the PI3K pathway is considered as a linear pathway, it
might be predicted that alterations affecting any event in the
pathway would have the same biological consequences and
thus would be redundant and mutually exclusive in cancer.
In some tumour types, this does indeed appear to be the
case. Thus for example, there is virtual mutual exclusivity
of RAS and PIK3CA mutation in endometrial cancer.
However, these mutations co-exist in colorectal cancer,
and in breast cancer HER2 amplification, PIK3CA mutation
and PTEN loss co-exist (reviewed in [12]).
In UC, genomic alterations in three of the key genes in
the pathway (PIK3CA, TSC1, PTEN) are not mutually
exclusive [23], implying that combined mutations have
additive or synergistic effects and that non-canonical effects
of these components may be critical drivers of bladder
cancer. This may be particularly important for TSC1. The
widely studied functions of both TSC1 and TSC2 are
attributed to the TSC1/TSC2 complex that regulates mTOR
activity via RHEB. Although some independent functions
have been ascribed to TSC2, independent function of TSC1
312 Cancer Metastasis Rev (2009) 28:305–316is not clear. The finding of mutations in bladder but not
other cancers and the lack of mutual exclusivity of TSC1
mutations with either PIK3CA or PTEN alterations may
indicate that TSC1 has an independent function in the
urothelium.
4 Therapeutic implications
The prominent role of the PI3K pathway in a wide range of
solid malignancies has led to major efforts to develop
agents that target components of the pathway. Discussion of
the wide range of inhibitors and approaches in development
is beyond the scope of this review and only a brief
comment will be given here. Two excellent recent reviews
provide detailed descriptions [84, 85].
Although there are currently no active clinical studies of
PI3K pathway inhibitors in UC, it is clear that these
tumours may benefit greatly from such agents. Several
classes of inhibitors may be relevant; dual PI3K-mTOR
inhibitors, PI3K inhibitors, AKT inhibitors and mTOR
inhibitors. Dual inhibitors of PI3K and mTOR reflect the
similarity in structure of these proteins, which has resulted
in the identification of small molecules that target both.
These typically target p110 α, β and δ isoforms, TORC1
and TORC2. This broad effect should potently inhibit
PI3K-AKT-TORC1 signalling. PI3K inhibitors are either
pan-PI3K or isoform specific. Pan inhibitors show side
effects including immunosuppression and glucose intoler-
ance. There is the theoretical advantage with isoform-
specific agents that these unwanted effects might be
avoided and, in cancers with specific dependence on a
single isoform, this approach may be preferable. However,
there are no p110α-specific agents yet in clinical trials. In
UC, where tumours show alterations at many levels in the
pathway, combined PI3K-mTOR inhibition may be a useful
approach, though may be relatively toxic.
As activation of mTOR can also be accomplished via the
MAPK pathway [11] (Fig. 1) it is likely that in tumours
with activation of this pathway in addition to the PI3K
pathway, inhibition of TORC1 cannot be achieved via
inhibition of the PI3K pathway alone. Similarly, tumours
with AKT1 mutation would not be predicted to respond to
PI3K inhibitors. In these cases, the specific AKT inhibitors
currently in phase I studies may be appropriate.
Rapamycin and its analogues inhibit TORC1 but not
TORC2. These have yet to be tested in UC but the known
feedback from TORC1 to AKT [86] raises concerns about
unwanted upstream activation of the pathway in the
presence of such inhibitors. mTOR catalytic site inhibitors
that can inhibit both TORC1 and TORC2 are in develop-
ment now. These should abrogate this feedback effect by
inhibiting AKT Ser473 phosphorylation by TORC2, though
as this may not prevent Thr308 phosphorylation, some
AKT activity might remain.
Inhibitors of upstream regulators (ERBB2/3; FGFRs)
and of other key pathways that are activated in UC, e.g., the
MAPK pathway are also relevant. The use of trastuzumab
in UC with gene amplification or high levels of over-
expression of ERBB2 has been suggested [87], though any
defects in the pathway below this would be predicted to
lead to resistance. Similarly, EGFR inhibitors might be
useful in certain cases. Proteins such as AKT that act lower
down in the pathway appear to be more attractive targets.
It is clear that whilst relevant inhibitors are available or
in development, it will be essential to have individual
tumour-specific information in order to apply these ratio-
nally. This is particularly important in light of the current
evidence that indicates non-redundancy of key molecular
events affecting pathway members in UC. The complexity
of feedback regulation of the pathway and its interactions
with other pathways, particularly the MAPK pathway
indicate that most successful treatments are likely to
involve combined targeting of two or more pathways.
Though the application of targeted agents will not be
straightforward, the availability of well-characterised UC
cell lines with known molecular profiles will greatly
facilitate preclinical testing both in vitro and in vivo.
5 Conclusions
Recent studies have identified multiple molecular mecha-
nisms by which the PI3K pathway is activated in bladder
tumours. It is already clear that non-canonical functions of
some pathway components may play a role in different
tumour subgroups and a key objective is to elucidate what
these are and to develop methods to classify tumour
samples according to the status of all of these functions.
This will allow patient selection for individualised targeted
therapy, drawing on the wealth of novel agents that will
soon be available.
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